Ieq Capital LLC Buys Shares of 26,102 United Therapeutics Corporation $UTHR

Ieq Capital LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 26,102 shares of the biotechnology company’s stock, valued at approximately $14,143,000.

A number of other institutional investors have also made changes to their positions in UTHR. Geneos Wealth Management Inc. raised its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 70 shares during the last quarter. Jump Financial LLC purchased a new position in shares of United Therapeutics during the 2nd quarter worth approximately $277,000. Cerity Partners LLC boosted its position in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia increased its holdings in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $513.12 on Friday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The company has a 50 day moving average price of $533.08 and a 200 day moving average price of $537.36. The stock has a market capitalization of $22.01 billion, a P/E ratio of 18.36, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter last year, the company posted $6.41 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 442,575 shares of company stock worth $239,326,330. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on UTHR shares. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Royal Bank Of Canada dropped their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.